Fruquintinib with programmed cell death ‐ 1 inhibitors versus triflueridine ‐ tipiracil ‐ 102 with bevacizumab in late‐line <scp>mCRC</scp> : A retrospective cohort study based on propensity score matching
Authors
Deyu Zeng
Hua Shen
Bo Li (ORCID: https://orcid.org/0000-0002-7315-3206)
Xiaolin Yang (ORCID: https://orcid.org/0000-0002-4902-8296)
H. Zhou (ORCID: https://orcid.org/0000-0003-2060-0436)
Li Ke
Wu Liu
Zhenyang Liu (ORCID: https://orcid.org/0000-0003-1323-7632)
Fruquintinib with programmed cell death ‐ 1 inhibitors versus triflueridine ‐ tipiracil ‐ 102 with bevacizumab in late‐line mCRC : A retrospective cohort study based on propensity score matching
Deyu Zeng, Hua Shen, Bo Li, Xiaolin Yang et al.
Journal
International Journal of Cancer
Topics
Colorectal Cancer Treatments and Studies
article
Fruquintinib with programmed cell death ‐ 1 inhibitors versus triflueridine ‐ tipiracil ‐ 102 with bevacizumab in late‐line mCRC : A retrospective cohort study based on propensity score matching
Deyu Zeng, Hua Shen, Bo Li, Xiaolin Yang, H. Zhou, Li Ke, Wu Liu, Zhenyang Liu, Yi‐Dong Zeng, Rong‐Rong Li, Shao‐Feng Jiang, Fang Xiang, Xian‐Li Yin
article en
Abstract
No abstract available for this paper.
Publication Tag
International Journal of CancerVol. 158(9)
Institutions
Central South University (CN), Kyoto University (JP), Hunan Cancer Hospital (CN)